Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FAZA-PET Hypoxia Imaging in Pancreatic Cancer
NCT02496832Withdrawn
- Sponsor
- University Health Network
- Start
- Nov 2014
- Primary completion
- Nov 2014
01
Overview
Open-label trial of Fluoroazomycin arabinoside F-18 in pancreatic adenocarcinoma (PDAC), sponsored by University Health Network. Primary endpoint: Expected vs actual number of similar quality scans at 2 years. Planned start Nov 2014; status: withdrawn.
02
Drugs
Fluoroazomycin arabinoside F-18
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02496832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02496832.